Shanghai, China-Recently, the second-generation balloon catheter-Alwide Plus Balloon Catheter (hereinafter referred to as "Alwide Plus") self-developed by MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) was approved for marketing by Saudi Food & Drug Authority.

As an upgraded product of Alwide^® valve balloon catheter, Alwide^® Plus was approved by the China National Drug Administration (NMPA) on July 29, 2021 and successfully launched in six overseas countries including Argentina, Colombia, Brazil, Thailand, Russia, and Indonesia, with its excellent performance widely recognized by the physicians: Its ultra-low compliance can realize more precise balloon expansion to avoid vascular damage; high burst pressure performance can effectively expand the site of severe calcification, which can better cope with the characteristics of Chinese patients with high calcification; fast filling and pumping performance can minimize the impact of prolonged blood flow blockage on cardiac function, reduce the pacing time, and lower the risk of surgery; significantly improved anti-puncture performance can further increase the safety of balloon dilatation while bring the surgeons a better experience.

Previously, MicroPort^® CardioFlow’s two generations of balloon catheters, Alwide^® and Alwide^® Plus, have been fully covered more than 500 hospitals in China and more than 80 hospitals in overseas countries since their listing. Its third generation balloon catheter, the AccuSniper™ Double-layer Balloon Catheter, has also been approved by the NMPA recently, which will provide patients with more high-quality and affordable treatment options.

As one of the fastest growing major economies in the world and the largest economy in the Middle East, Saudi Arabia's high-end medical device market has great potential for development. The approval of Alwide^® Plus in Saudi Arabia will help more overseas TAVI physicians to meet the challenges of different types of surgeries, and benefit more local patients with structural heart disease. At present, the registration of VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System self-developed by MicroPort^® CardioFlow has also made progress in Saudi Arabia.

In the future, MicroPort^® CardioFlow will continue to invest in technology and product innovation, and be dedicated to providing high-quality, universal total solutions for structural heart disease to more patients around the world.

Notes: 

[1] MicroPort^® CardioFlow Laboratory Test Data (vs. Alwide^® Balloon Catheter)